Telemedics
Preço: 72.91Empresa e modelo de negócios
Telemedics (TMDX.US) operates in the healthcare sector, focusing on advanced telemedicine solutions. Its core products include remote patient monitoring systems and digital health platforms that facilitate virtual consultations and data analytics. The company generates revenue primarily through subscription services and software licensing, catering to healthcare providers and patients.
Perfil de investimento
The investment profile of Telemedics is more aligned with balanced investors, given its moderate growth potential and current market position. The absence of dividends and the high risk associated with its operations suggest a cautious approach. The stock may appeal to those looking for a mix of growth and stability over a medium to long-term horizon.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 5.03 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- 8.2% ↑
- Surpresa de EPS
- -51.6% pior que o esperado
- Volatilidade 20d
- 2.8% estável
Impacto da previsão
neutroAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-03 02:54 | Manter | Vender | Weak fundamentals and negative momentum indicate high risk. |
| 2026-05-08 15:07 | — | Manter | Weak momentum and high risk overshadow potential growth. |
| 2026-05-08 05:33 | Manter | Manter | Компания демонстрирует значительное снижение цен на акции за последние месяцы, что указывает на высокие риски. Несмотря на положительные показатели EPS и рост выручки, текущая динамика цен не внушает доверия. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-26 10:50 | Stifel Nicolaus | Preço-alvo reduzido | 85 → 75 | 68.935 |
| 2026-05-06 13:42 | Needham | Preço-alvo reduzido | 174 → 142 | 73.8351 |
| 2026-05-06 11:46 | Canaccord Genuity | Preço-alvo reduzido | 152 → 124 | 94.93 |
Nada ainda